Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1693
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283242 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18506430 | REPRESSOR PROTEINS FOR GENE REGULATION AND CRISPR INTERFERENCE | Non-Final OA | Georgia Tech Research Corporation |
| 18270014 | Suppression-Replacement Gene Therapy | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | Final Rejection | The Regents of the University of California |
| 18186290 | IN VITRO GENETIC DISEASE MODEL CELL AND METHOD FOR PRODUCING THE SAME | Final Rejection | RICOH COMPANY, LTD. |
| 17059692 | MODIFIED NUCLEIC ACID INHIBITING MICRO RNA, AND USE THEREOF | Final Rejection | Korea University Research and Business Foundation |
| 18287711 | AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18276471 | NUCLEASE-GUIDED NON-LTR RETROTRANSPOSONS AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 18015102 | NUTRITIONAL COMPOSITION COMPRISING MIR-3141 | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 16966851 | COMPOSITIONS AND METHODS FOR INDUCING TRIPARTITE MOTIF-CONTAINING PROTEIN 16 (TRIM16) SIGNALING | Final Rejection | University of Washington |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17435365 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | Final Rejection | The Trustees of the University of Pennsylvania |
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17282335 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Non-Final OA | Ionis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy